Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
5.930
USD
+0.280 (+4.96%)
Official Closing Price
Updated: 4:33 PM EST, Nov 23, 2020
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Today 8:00 EST
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today...
From
PR Newswire
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
November 10, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today...
From
PR Newswire
Ardelyx to Webcast Virtual Analyst Day
November 06, 2020
--Featuring a panel of distinguished guest speakers--
From
PR Newswire
Analysts Expect 56% Upside For XBI
November 06, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
November 05, 2020
Tenapanor NDA Accepted for Review by FDA; PDUFA Goal Date set for April 29, 2021
From
PR Newswire
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
October 22, 2020
--Data presented across five posters continue to support the foundational role tenapanorcould play in the treatment of hyperphosphatemia--
From
PR Newswire
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
October 22, 2020
--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia--
From
PR Newswire
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
October 12, 2020
--Comprehensive datasets demonstrate tenapanor's ability to control serum phosphorous in patients with chronic kidney disease (CKD) on dialysis--
From
PR Newswire
TUSA's Underlying Holdings Could Mean 10% Gain Potential
October 06, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
First Week of November 20th Options Trading For Ardelyx (ARDX)
September 18, 2020
Investors in Ardelyx Inc (ARDX) saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain...
Tags
Stocks
From
Market News Video
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
September 15, 2020
NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy
From
PR Newswire
Ardelyx to Participate in Three Upcoming Investor Conferences in September
September 08, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced that...
From
PR Newswire
How The Parts Add Up: LABU Targets $79
September 03, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 06, 2020
Submitted a New Drug Application to the U.S. Food and Drug Administration for the review of tenapanor as a first-in-class therapy to control serum phosphorus in adult patients with chronic kidney...
From
PR Newswire
Analysts See 45% Gains Ahead For XBI
August 03, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
August 03, 2020
A New Drug Application for the Review of Tenapanor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis has Been Submitted to the FDA
From
PR Newswire
First Week of ARDX September 18th Options Trading
July 20, 2020
Investors in Ardelyx Inc (ARDX) saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options...
Tags
Stocks
From
Market News Video
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
June 30, 2020
Application is Supported by Three Positive Phase 3 Clinical Trials for Tenapanor for Hyperphosphatemia, a Condition which affects Approximately 85% of CKD Patients on Dialysis
From
PR Newswire
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
June 15, 2020
Foundational use of tenapanor as monotherapy or with sevelamer enabled up to 47.4% of patients to achieve normal serum phosphorus levels (<4.6 mg/dL), a 58% improvement over current standard of care
From
PR Newswire
Ardelyx (ARDX) Shares Cross Below 200 DMA
June 11, 2020
In trading on Thursday, shares of Ardelyx Inc (ARDX) crossed below their 200 day moving average of $6.38, changing hands as low as $6.25 per share. Ardelyx Inc shares are currently trading down about...
Tags
Stocks
From
Market News Video
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 09, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,...
From
PR Newswire
The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates
June 09, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
FENC
NNVC
RTRX
From
Benzinga
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
June 08, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,...
From
PR Newswire
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
May 26, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,...
From
PR Newswire
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 21, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,...
From
PR Newswire
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
May 18, 2020
Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases,...
From
PR Newswire
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
May 07, 2020
Company maintains strong balance sheet with $223.2 million in cash, cash equivalents and short-term investments
From
PR Newswire
How The Pieces Add Up: DWAS Headed For $55
April 22, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Knight Therapeutics Announces Approval of IBSRELA™ in Canada
April 17, 2020
From
GlobeNewswire News Releases
Interesting ARDX Put And Call Options For May 15th
March 27, 2020
Investors in Ardelyx Inc (ARDX) saw new options become available this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARDX options chain...
Tags
Stocks
From
Market News Video
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
